Peter Weinstein
Chief Executive Officer Circurna
Seminars
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
Wednesday 22nd July 2026
A Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different DiseasesA Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different Diseases
11:40 am
- Showcasing the development of a circular RNA platform that is room temperature stable, durable for a long period of time in vivo after administration and results in very high protein production starting shortly after administration
- Administrating circular RNA using microneedle patches resulting in preferential targeting of the circular RNA to the cells that produce protein in vivo to treat cancers, autoimmune, fibrosis and other diseases and will be used on human patients as part of Circurna’s first Phase I clinical trial in early 2027
- Developing a novel and industry leading purification manufacturing protocol that results in high circularization, high yield, high purity at a low cost
